Selecta Biosciences JDRF have extended their pharma partnership and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes.This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas.
Selecta’s proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs.
JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic.
This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Sanofi
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity